Published September 1, 2023 | Version v2
Book Open

Unlocking the power of computational modelling and simulation across the product lifecycle in life sciences: A UK Landscape Report

  • 1. University of Leeds
  • 2. University of Oxford
  • 3. Medicines and Healthcare products Regulatory Agency
  • 4. Medicines and Healthcare products Regulatory Agency h
  • 5. Association of British HealthTech Industries
  • 6. BSI Group
  • 7. Element Material Technology
  • 8. Medtronic
  • 9. Boston Scientific
  • 10. DePuy Synthes, Johnson and Johnson
  • 11. Philips Healthcare
  • 12. Edwards Lifesciences
  • 13. ANSYS
  • 14. Dassault Systèmes
  • 15. Synopsys
  • 16. adsilico
  • 17. Imperial College
  • 18. University College London
  • 19. University of Sheffield
  • 20. Scientific Writer


This report

  • Outlines the public health and economic benefits of using in silico technologies (ISTs) to refine, reduce, and even replace the need for conventional human clinical trials and animal and physical testing in the development of new medical products,
  • Describes current barriers to the expanded use of ISTs,
  • Identifies opportunities for the UK to spearhead the global effort to develop ISTs, making the UK a leader in the field and, therefore, friendly to inward investors,
  • Details the significant commercial and economic benefits in the development of the UK life sciences sector and broader societal benefits to the NHS, UK, and the world in general,
  • Makes recommendations on how the UK government can support this industrial and regulatory transition.


InnovateUK KTN and the Royal Academy of Engineering Chair in Emerging Technology (INSILEX CiET1819/19) funded this report. We also acknowledge contributions from many members of the InSilicoUK Innovation Network (


Frangi_et_al_ InSilicoUK_LandscapeReport_2023_final.pdf

Files (10.0 MB)